Addressing Racial & Socioeconomic Disparities in Access to Medications for Opioid Use Disorder Amid COVID-19

Overview

Journal J Subst Abuse Treat

Specialty Psychiatry

Date 2020 Nov 29

PMID 33248862

Citations 31

Authors

Max Jordan Nguemeni Tiako

Affiliations

Soon will be listed here.

Citing Articles

Virtual Primary Care for People With Opioid Use Disorder: Scoping Review of Current Strategies, Benefits, and Challenges.

Narayan S, Gooderham E, Spencer S, McCracken R, Hedden L J Med Internet Res. 2024; 26:e54015.

PMID: 39622042 PMC: 11650090. DOI: 10.2196/54015.

Integrating Nursing Practice and Policy in Opioid Overdose Prevention: Analysis of the Opioid-Overdose Reduction Continuum of Care Approach Practice Guide.

Kyei E, Ansong R, Kyei G J Adv Nurs. 2024; 81(3):1276-1285.

PMID: 39253795 PMC: 11810498. DOI: 10.1111/jan.16451.

Associations between mental health & substance use treatment and alcohol use progression and recovery among US women drinkers.

Young A, Reboussin B, Riehm K, Mojtabai R, Green K, OGorman E PLoS One. 2024; 19(7):e0306820.

PMID: 38976705 PMC: 11230554. DOI: 10.1371/journal.pone.0306820.

Emergency department staff compassion is associated with lower fear of enacted stigma among patients with opioid use disorder.

Steinhauser S, Haroz R, Jones I, Skelton W, Fuller B, Roberts M Acad Emerg Med. 2024; 31(12):1204-1211.

PMID: 38881343 PMC: 11649595. DOI: 10.1111/acem.14970.

Social and cognitive determinants of medications for opioid use disorder outcomes: A systematic review using a social determinants of health framework.

Hernandez-Vallant A, Hurlocker M Appl Neuropsychol Adult. 2024; :1-25.

PMID: 38662711 PMC: 11502508. DOI: 10.1080/23279095.2024.2336195.

References

Carlson R, Daniulaityte R, Silverstein S, Nahhas R, Martins S . Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose?. Int J Drug Policy. 2020; 79:102722. PMC: 9387534. DOI: 10.1016/j.drugpo.2020.102722. View

Wakeman S, Larochelle M, Ameli O, Chaisson C, McPheeters J, Crown W . Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Netw Open. 2020; 3(2):e1920622. PMC: 11143463. DOI: 10.1001/jamanetworkopen.2019.20622. View

Edelman E, Oldfield B, Tetrault J . Office-Based Addiction Treatment in Primary Care: Approaches That Work. Med Clin North Am. 2018; 102(4):635-652. DOI: 10.1016/j.mcna.2018.02.007. View

Yarborough B, Stumbo S, McCarty D, Mertens J, Weisner C, Green C . Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis. Drug Alcohol Depend. 2016; 160:112-8. PMC: 4767611. DOI: 10.1016/j.drugalcdep.2015.12.031. View

Khan N, Bateman B, Landon J, Gagne J . Association of Opioid Overdose With Opioid Prescriptions to Family Members. JAMA Intern Med. 2019; 179(9):1186-1192. PMC: 6593630. DOI: 10.1001/jamainternmed.2019.1064. View

Reichert J, Gleicher L . Probation clients' barriers to access and use of opioid use disorder medications. Health Justice. 2019; 7(1):10. PMC: 6717960. DOI: 10.1186/s40352-019-0089-6. View

Wang Q, Kaelber D, Xu R, Volkow N . COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2020; 26(1):30-39. PMC: 7488216. DOI: 10.1038/s41380-020-00880-7. View

Wightman R, Perrone J, Scagos R, Krieger M, Nelson L, Marshall B . Opioid Overdose Deaths with Buprenorphine Detected in Postmortem Toxicology: a Retrospective Analysis. J Med Toxicol. 2020; 17(1):10-15. PMC: 7785599. DOI: 10.1007/s13181-020-00795-3. View

Kilaru A, Xiong A, Lowenstein M, Meisel Z, Perrone J, Khatri U . Incidence of Treatment for Opioid Use Disorder Following Nonfatal Overdose in Commercially Insured Patients. JAMA Netw Open. 2020; 3(5):e205852. PMC: 7254182. DOI: 10.1001/jamanetworkopen.2020.5852. View

10.

Morgan J, Schackman B, Weinstein Z, Walley A, Linas B . Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug Alcohol Depend. 2019; 200:34-39. PMC: 6613830. DOI: 10.1016/j.drugalcdep.2019.02.031. View

11.

James K, Jordan A . The Opioid Crisis in Black Communities. J Law Med Ethics. 2018; 46(2):404-421. DOI: 10.1177/1073110518782949. View

12.

Hansen H, Siegel C, Case B, Bertollo D, DiRocco D, Galanter M . Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City. J Behav Health Serv Res. 2013; 40(3):367-77. PMC: 3818282. DOI: 10.1007/s11414-013-9341-3. View

13.

Stein B, Dick A, Sorbero M, Gordon A, Burns R, Leslie D . A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees. Subst Abus. 2018; 39(4):419-425. PMC: 6309581. DOI: 10.1080/08897077.2018.1449166. View

14.

Bourgois P . Disciplining addictions: the bio-politics of methadone and heroin in the United States. Cult Med Psychiatry. 2000; 24(2):165-95. DOI: 10.1023/a:1005574918294. View

15.

Yang J, Landrum M, Zhou L, Busch A . Disparities in outpatient visits for mental health and/or substance use disorders during the COVID surge and partial reopening in Massachusetts. Gen Hosp Psychiatry. 2020; 67:100-106. PMC: 7550185. DOI: 10.1016/j.genhosppsych.2020.09.004. View

16.

Roberts A, Saloner B, Dusetzina S . Buprenorphine Use and Spending for Opioid Use Disorder Treatment: Trends From 2003 to 2015. Psychiatr Serv. 2018; 69(7):832-835. PMC: 6028283. DOI: 10.1176/appi.ps.201700315. View

17.

Andraka-Christou B, Gabriel M, Madeira J, Silverman R . Court personnel attitudes towards medication-assisted treatment: A state-wide survey. J Subst Abuse Treat. 2019; 104:72-82. DOI: 10.1016/j.jsat.2019.06.011. View

18.

Harris S . To Be Free and Normal: Addiction, Governance, and the Therapeutics of Buprenorphine. Med Anthropol Q. 2015; 29(4):512-30. PMC: 4689659. DOI: 10.1111/maq.12232. View

19.

Goedel W, Shapiro A, Cerda M, Tsai J, Hadland S, Marshall B . Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States. JAMA Netw Open. 2020; 3(4):e203711. PMC: 7177200. DOI: 10.1001/jamanetworkopen.2020.3711. View

20.

Finkelstein Y, Macdonald E, Gonzalez A, Sivilotti M, Mamdani M, Juurlink D . Overdose Risk in Young Children of Women Prescribed Opioids. Pediatrics. 2017; 139(3). DOI: 10.1542/peds.2016-2887. View